Canada · Delayed Price · Currency is CAD NeuPath Health Statistics
Total Valuation
NeuPath Health has a market cap or net worth of CAD 30.77 million. The enterprise value is 40.17 million.
| Market Cap | 30.77M |
| Enterprise Value | 40.17M |
Important Dates
The last earnings date was Thursday, November 12, 2026.
| Earnings Date | Nov 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
NeuPath Health has 56.98 million shares outstanding. The number of shares has increased by 7.14% in one year.
| Current Share Class | 56.98M |
| Shares Outstanding | 56.98M |
| Shares Change (YoY) | +7.14% |
| Shares Change (QoQ) | +0.87% |
| Owned by Insiders (%) | 5.42% |
| Owned by Institutions (%) | 10.83% |
| Float | 49.03M |
Valuation Ratios
The trailing PE ratio is 18.78 and the forward PE ratio is 6.00.
| PE Ratio | 18.78 |
| Forward PE | 6.00 |
| PS Ratio | 0.34 |
| PB Ratio | 1.33 |
| P/TBV Ratio | 16.13 |
| P/FCF Ratio | 15.31 |
| P/OCF Ratio | 9.65 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 8.26, with an EV/FCF ratio of 19.98.
| EV / Earnings | 24.75 |
| EV / Sales | 0.45 |
| EV / EBITDA | 8.26 |
| EV / EBIT | 15.65 |
| EV / FCF | 19.98 |
Financial Position
The company has a current ratio of 1.16, with a Debt / Equity ratio of 0.54.
| Current Ratio | 1.16 |
| Quick Ratio | 1.10 |
| Debt / Equity | 0.54 |
| Debt / EBITDA | 2.64 |
| Debt / FCF | 6.40 |
| Interest Coverage | 3.38 |
Financial Efficiency
Return on equity (ROE) is 8.67% and return on invested capital (ROIC) is 7.83%.
| Return on Equity (ROE) | 8.67% |
| Return on Assets (ROA) | 3.45% |
| Return on Invested Capital (ROIC) | 7.83% |
| Return on Capital Employed (ROCE) | 7.44% |
| Weighted Average Cost of Capital (WACC) | 7.59% |
| Revenue Per Employee | 587,053 |
| Profits Per Employee | 10,678 |
| Employee Count | 152 |
| Asset Turnover | 1.92 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -750,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +47.95% in the last 52 weeks. The beta is 0.83, so NeuPath Health's price volatility has been lower than the market average.
| Beta (5Y) | 0.83 |
| 52-Week Price Change | +47.95% |
| 50-Day Moving Average | 0.55 |
| 200-Day Moving Average | 0.55 |
| Relative Strength Index (RSI) | 46.99 |
| Average Volume (20 Days) | 91,575 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, NeuPath Health had revenue of CAD 89.23 million and earned 1.62 million in profits. Earnings per share was 0.03.
| Revenue | 89.23M |
| Gross Profit | 16.60M |
| Operating Income | 2.57M |
| Pretax Income | 1.20M |
| Net Income | 1.62M |
| EBITDA | 3.58M |
| EBIT | 2.57M |
| Earnings Per Share (EPS) | 0.03 |
Balance Sheet
The company has 4.04 million in cash and 12.85 million in debt, with a net cash position of -8.82 million or -0.15 per share.
| Cash & Cash Equivalents | 4.04M |
| Total Debt | 12.85M |
| Net Cash | -8.82M |
| Net Cash Per Share | -0.15 |
| Equity (Book Value) | 23.66M |
| Book Value Per Share | 0.41 |
| Working Capital | 1.96M |
Cash Flow
In the last 12 months, operating cash flow was 3.19 million and capital expenditures -1.18 million, giving a free cash flow of 2.01 million.
| Operating Cash Flow | 3.19M |
| Capital Expenditures | -1.18M |
| Depreciation & Amortization | 1.01M |
| Net Borrowing | -2.27M |
| Free Cash Flow | 2.01M |
| FCF Per Share | 0.04 |
Margins
Gross margin is 18.60%, with operating and profit margins of 2.88% and 1.82%.
| Gross Margin | 18.60% |
| Operating Margin | 2.88% |
| Pretax Margin | 1.34% |
| Profit Margin | 1.82% |
| EBITDA Margin | 4.01% |
| EBIT Margin | 2.88% |
| FCF Margin | 2.25% |
Dividends & Yields
NeuPath Health does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -7.14% |
| Shareholder Yield | -7.14% |
| Earnings Yield | 5.33% |
| FCF Yield | 6.53% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Analyst Forecast
The average price target for NeuPath Health is 0.82, which is 50.93% higher than the current price. The consensus rating is "Buy".
| Price Target | 0.82 |
| Price Target Difference | 50.93% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 7 |